Effect of Hsp90 Inhbitors on differentiation antigens and MHC Class I.

aCells were untreated (control) or treated with 5000 Units/ml of IFN-beta, or with the Hsp90 inhibitors as indicated for 3 days.bDose indicated is optimal dose for antigen increasecNumber represents geometric mean of intracellular staining with an antibody to Melan-A/MART-1, gp100 or TRP-2 of live gated cells. Number is parenthesis is fold increase relative to untreated control.dNumber represents geometric mean of surface staining with the MHC Class I antibody W6/32 (or H2kb for B16) of live gated cells.Antigen status of human melanoma cell lines: (+) = Melan-A/MART-1and gp100 high (-) = Melan-A/MART-1and gp100 low.n.a. = not applicable, glioma do not express Melan-A/MART-1, and human Melan-A/MART-1 antibody did not cross react with murine Melan-A/MART-1n.d. = not determined; these cells were not stained with the TRP-2 antibody.Effect of Hsp90 Inhbitors on differentiation antigens and MHC Class I.